Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Biohaven Ltd.NYSE: BHVN

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) growth accelerates

Q2 FY2026 weighted avg shares (diluted) of 150.64M shares rose 47.1% year over year, ahead of the +31.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +34.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +47.1% holds above the trailing-twelve-month pace of +31.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
150.64M+2.0% QoQ
Last fiscal yearDec 2025
107.62M+18.0% YoY
LTMJun 2026
131.06M+31.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.1%——
1 year+18.0%——
3-year CAGR+34.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
107.62M USD
Year-over-year change
+18.0%
4-year CAGR
+31.7%

Weighted Avg Shares (Diluted) vs competitors

How BHVN compares with its peers on the latest reported figures

  • BHVN's LTM Jun 2026 weighted avg shares (diluted) of 131.06M shares is the 3rd highest of the 11 companies compared; the peer median is 70.1M shares.
  • Its year-over-year change of +31.1% is the 2nd highest of 11, against a peer median of +11.5%.
  • Over three fiscal years its annual growth of +34.0% compares with a peer median of +10.2%.
BHVN Competitors Peer median
Weighted Avg Shares (Diluted) for BHVN and competitors
Company Period LTM YoY 3-year CAGR
ABCLAbCellera Biologics Inc.LTM Sep 2026306.35M +3.0%-1.7%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026172.82M +15.4%+8.4%
BHVNBiohaven Ltd.LTM Jun 2026131.06M +31.1%+34.0%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
VERAVera Therapeutics, Inc.LTM Jun 202667.85M +14.4%+34.2%
PHVSPharvaris N.V.LTM Sep 202665.72M +16.6%+20.8%
IMCRImmunocore Holdings plcLTM Mar 202650.99M -0.4%+3.3%
ZBIOZenas BioPharma, Inc.LTM Mar 202646.54M +13.7%+5.3%
SIONSionna Therapeutics, Inc.LTM Mar 202643.37M -1.7%-3.2%
Peer median (excluding BHVN) 70.1M+11.5%+10.2%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.14M
Gross Profit0000(4.14M)
Gross Margin—————
Research & Development181.49M437.07M373.28M795.87M635.07M
Selling, General & Admin37.41M130.86M62.77M89.24M106.17M
Operating Expenses218.9M567.93M436.05M885.11M741.24M
Depreciation & Amortization1.39M1.39M6.91M7.86M9.92M
EBITDA(211.04M)(568.46M)(402.64M)(837.83M)(727.46M)
EBITDA Margin—————
Operating Income(218.9M)(567.93M)(436.05M)(885.11M)(745.38M)
Operating Margin—————
Interest Income0017.73M21.33M14.59M
Interest Expense00000
Other Income / Expenses6.47M(1.91M)26.5M39.42M8M
Income Before Tax(212.43M)(569.84M)(409.55M)(845.69M)(737.38M)
Pre-Tax Margin—————
Income Tax Expense1.37M438K(1.38M)735K1.44M
Net Income(213.8M)(570.28M)(408.17M)(846.42M)(738.82M)
Net Margin—————
EPS (Basic)(5.97)(12.75)(5.73)(9.28)(6.86)
EPS (Diluted)(5.97)(12.75)(5.73)(9.28)(6.86)
Weighted Avg Shares35.82M44.74M71.2M91.23M107.62M
Weighted Avg Shares (Diluted)35.82M44.74M71.2M91.23M107.62M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.